Skip to main content

ZyVersa Therapeutics, Inc.

corporate_fare Company Profile

ZyVersa Therapeutics, Inc.

ZVSA·OTC·Life Sciences·CIK 0001859007

ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops drugs for patients with chronic renal or inflammatory diseases. The company uses two proprietary, globally licensed drug development platforms, both discovered by research scientists at the University of Miami, Miller School of Medicine. The first platform is Cholesterol Efflux Mediator VAR 200 (2-hydroxypropyl-beta-cyclodextrin or "2HPβCD"), an injectable drug in clinical development for renal diseases. VAR 200 was licensed from L&F Research LLC on December 15, 2015. ZyVersa's renal pipeline initially targets rare, chronic glomerular diseases, with its lead indication for VAR 200 being focal segmental glomerulosclerosis ("FSGS"). The company plans to start a Phase 2a basket trial in FSGS and Alport syndrome patients in Q2-2026. VAR 200 has pharmacologic proof-of-concept data in animal models for FSGS, Alport Syndrome, and diabetic kidney disease. The second platform is Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody in preclinical development for inflammatory conditions. IC 100 was licensed from InflamaCore, LLC on April 18, 2019. This platform focuses on chronic inflammatory diseases, with its lead indication for IC 100 being cardiometabolic conditions associated with obesity. IC 100's preclinical development is nearing completion.

ZyVersa Therapeutics, Inc. (OTC:ZVSA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for ZVSA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-05-13, rated 7/10. Across its 3 most recent items scored 7 or higher, the top rating is 9/10, with 2 rated 8 or above. Recent SEC coverage for ZVSA spans 10-K, 8-K.

Recent high-impact activity:

  • ZyVersa Therapeutics Reports $0 Revenue, $1.79M Net Loss in Q1 Amid Ongoing Liquidity Concerns
  • ZyVersa Faces Going Concern Doubt, Nasdaq Delisting, and $18.6M R&D Impairment
  • ZyVersa Therapeutics Secures $1M in Highly Dilutive Convertible Note and Warrant Offering

Short Interest & Short Volume

238.20 days to cover

FINRA reported short interest of 138,394 shares in ZVSA as of the October 30, 2026 settlement, unchanged from the prior period — about 238.2 days to cover at its recent average daily volume. On November 12, 2026, 86.2% of ZVSA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)138,394 shares as of October 30, 2026
Change vs prior period 0.0%
Days to cover238.20 at avg daily volume of 581
Daily short volume (FINRA facilities)86.2% of 3,676 shares on November 12, 2026

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

No longer listed

ZVSA (ZyVersa Therapeutics, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed ZVSA - Latest Insights

ZVSA
May 13, 2026, 4:51 PM EDT
Source: Wiseek News
Importance Score:
7
ZVSA
Mar 31, 2026, 4:54 PM EDT
Filing Type: 10-K
Importance Score:
9
ZVSA
Mar 05, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets